Tekla Healthcare Investors
Tekla Healthcare Investors (HQH) Financial Performance & Income Statement Overview
Review Tekla Healthcare Investors (HQH) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Tekla Healthcare Investors (HQH) Income Statement & Financial Overview
View the income breakdown for Tekla Healthcare Investors HQH across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $5.46M | $5.31M | $2.65M | $75.24M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $5.40M |
| Gross Profit | $5.46M | $5.31M | $2.65M | $69.84M |
| Gross Profit Ratio | $1.00 | $1.00 | $1.00 | $0.93 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $5.65M | $5.34M | $2.67M | $2.84M |
| Operating Expenses | $5.65M | $5.34M | $47.20M | $15.75M |
| Total Costs & Expenses | $5.65M | $5.34M | $47.20M | $102.06M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $189149.00 | $31122.00 | $15561.00 | $511167.00 |
| EBITDA | $0.00 | $0.00 | $49.86M | -$26.82M |
| EBITDA Ratio | $0.00 | $0.00 | $18.80 | -$0.36 |
| Operating Income | -$189149.00 | -$31122.00 | -$15561.00 | -$26.82M |
| Operating Income Ratio | -$0.03 | -$0.006 | -$0.006 | -$0.36 |
| Other Income/Expenses (Net) | $85.44M | $99.73M | $49.86M | -$6979.00 |
| Income Before Tax | $85.25M | $99.70M | $49.85M | -$26.83M |
| Income Before Tax Ratio | $15.60 | $18.79 | $18.79 | -$0.36 |
| Income Tax Expense | $0.00 | $0.00 | $49.86M | -$1.00 |
| Net Income | $85.25M | $99.70M | $49.85M | -$26.83M |
| Net Income Ratio | $15.60 | $18.79 | $18.79 | -$0.36 |
| EPS | $1.59 | $1.97 | $0.98 | -$0.54 |
| Diluted EPS | $1.59 | $1.97 | $0.98 | -$0.54 |
| Weighted Avg Shares Outstanding | $53.63M | $50.62M | $50.62M | $49.44M |
| Weighted Avg Shares Outstanding (Diluted) | $53.63M | $50.62M | $50.62M | $49.44M |
Over the past four quarters, Tekla Healthcare Investors demonstrated steady revenue growth, increasing from $75.24M in Q3 2023 to $5.46M in Q4 2024. Operating income reached -$189149.00 in Q4 2024, maintaining a consistent -3% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $0.00, reflecting operational efficiency. Net income dropped to $85.25M, with EPS at $1.59. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan